Developmental Funds support the Lineberger Comprehensive Cancer Center (LCCC) mission directly through the provision of resources and indirectly by leveraging institutional and philanthropic assets. Collectively, these resources expand and enhance cancer research across LCCC in the basic, clinical, population and translational sciences. During the last five years, these funds have been used to make key recruitments, to launch innovative ideas, and to make technical advances within our Shared Resources. Through these expenditures, the LCCC bolstered interdisciplinary and translational research efforts. By objective criteria, e.g. extramural grants funded, and junior faculty garnering national awards, our recruitment and retention efforts have been a stunning success. Our range of pilot project awards have initiated new research across the clinical, population, translational, and basic spectrum, again yielding success in seeding extramural grant funding, broad collaborations, and cancer related publications. The funds provided for Shared Resources have developed new techniques, particularly those translating fundamental discoveries into clinical applications. A decision by NCI three years into this cycle allowed expenditures of Developmental Funds for projects outside the borders of the United States. We were please to utilize this capability to fund pilot projects in our initiatives in sub-Saharan Africa that have led to significant NCI grant funding. While we retained the capability of using Developmental Funds for bridge funding, we did not utilize any Development Funds for this in the last cycle. As has been the case over the last decade, Developmental Funds have been key in the growth of the Center's scientific and clinical impact. LCCC requests $50,000 increase in this category, to $700,000 per year, in this renewal application, justified by past success and needs for a growing Center. We will continue to use these funds in recruitment, pilot projects, and Shared Resource development and retain the potential for interim (bridge) funding.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016086-43
Application #
9614899
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2018-12-01
Budget End
2019-11-30
Support Year
43
Fiscal Year
2019
Total Cost
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Hu, Peirong; Bi, Yanmin; Ma, Hong et al. (2018) Superior lentiviral vectors designed for BSL-0 environment abolish vector mobilization. Gene Ther 25:454-472
Townsley, Loni; Yannarell, Sarah M; Huynh, Tuanh Ngoc et al. (2018) Cyclic di-AMP Acts as an Extracellular Signal That Impacts Bacillus subtilis Biofilm Formation and Plant Attachment. MBio 9:
Schulfer, Anjelique F; Battaglia, Thomas; Alvarez, Yelina et al. (2018) Intergenerational transfer of antibiotic-perturbed microbiota enhances colitis in susceptible mice. Nat Microbiol 3:234-242
Hall, Marissa G; Mendel, Jennifer R; Noar, Seth M et al. (2018) Why smokers avoid cigarette pack risk messages: Two randomized clinical trials in the United States. Soc Sci Med 213:165-172
Cholon, Deborah M; Gentzsch, Martina (2018) Recent progress in translational cystic fibrosis research using precision medicine strategies. J Cyst Fibros 17:S52-S60
Tappata, Manaswita; Eluri, Swathi; Perjar, Irina et al. (2018) Association of mast cells with clinical, endoscopic, and histologic findings in adults with eosinophilic esophagitis. Allergy 73:2088-2092
Che, Tao; Majumdar, Susruta; Zaidi, Saheem A et al. (2018) Structure of the Nanobody-Stabilized Active State of the Kappa Opioid Receptor. Cell 172:55-67.e15
Cranston, Ross D; Cespedes, Michelle S; Paczuski, Pawel et al. (2018) High Baseline Anal Human Papillomavirus and Abnormal Anal Cytology in a Phase 3 Trial of the Quadrivalent Human Papillomavirus Vaccine in Human Immunodeficiency Virus-Infected Individuals Older Than 26 Years: ACTG 5298. Sex Transm Dis 45:266-271
DeBono, Nathan L; Robinson, Whitney R; Lund, Jennifer L et al. (2018) Race, Menopausal Hormone Therapy, and Invasive Breast Cancer in the Carolina Breast Cancer Study. J Womens Health (Larchmt) 27:377-386
Okolie, Onyinyechukwu; Irvin, David M; Bago, Juli R et al. (2018) Intra-cavity stem cell therapy inhibits tumor progression in a novel murine model of medulloblastoma surgical resection. PLoS One 13:e0198596

Showing the most recent 10 out of 1525 publications